Providing a diverse range of perspectives from bullish to bearish, 5 analysts have published ratings on Beauty Health SKIN in the last three months.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 0 | 0 | 4 | 1 | 0 |
| Last 30D | 0 | 0 | 1 | 0 | 0 |
| 1M Ago | 0 | 0 | 3 | 1 | 0 |
| 2M Ago | 0 | 0 | 0 | 0 | 0 |
| 3M Ago | 0 | 0 | 0 | 0 | 0 |
Analysts have recently evaluated Beauty Health and provided 12-month price targets. The average target is $3.6, accompanied by a high estimate of $4.00 and a low estimate of $3.00. This current average has increased by 38.46% from the previous average price target of $2.60.
Exploring Analyst Ratings: An In-Depth Overview
In examining recent analyst actions, we gain insights into how financial experts perceive Beauty Health. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Susan Anderson | Canaccord Genuity | Raises | Hold | $4.00 | $3.00 |
| Korinne Wolfmeyer | Piper Sandler | Raises | Underweight | $3.00 | $2.00 |
| Jonathan Block | Stifel | Raises | Hold | $4.00 | $3.00 |
| Oliver Chen | TD Cowen | Raises | Market Perform | $4.00 | $2.50 |
| Susan Anderson | Canaccord Genuity | Raises | Hold | $3.00 | $2.50 |
Key Insights:
- Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Beauty Health. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Beauty Health compared to the broader market.
- Price Targets: Gaining insights, analysts provide estimates for the future value of Beauty Health's stock. This comparison reveals trends in analysts' expectations over time.
Capture valuable insights into Beauty Health's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
Stay up to date on Beauty Health analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
Discovering Beauty Health: A Closer Look
The Beauty Health Co is a category-creating beauty health company that along with its subsidiaries designs, develops, manufactures, markets, and sells esthetic technologies and products. The company's brand portfolio includes Hydrafacial, SkinStylus, and Keravive, offering Syndeo device, SkinStylus SteriLock Microsystem, Keravive Peptide Solution and other products.
Beauty Health's Financial Performance
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Decline in Revenue: Over the 3 months period, Beauty Health faced challenges, resulting in a decline of approximately -1.34% in revenue growth as of 31 December, 2023. This signifies a reduction in the company's top-line earnings. When compared to others in the Consumer Staples sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Beauty Health's net margin is impressive, surpassing industry averages. With a net margin of -9.71%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Beauty Health's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -12.59%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Beauty Health's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -0.99% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Beauty Health's debt-to-equity ratio stands notably higher than the industry average, reaching 12.67. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
How Are Analyst Ratings Determined?
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
